| Title |
High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer
|
|---|---|
| Published in |
Tumor Biology, April 2014
|
| DOI | 10.1007/s13277-014-1932-y |
| Pubmed ID | |
| Authors |
Rumeysa Ciftci, Faruk Tas, Ceren Tilgen Yasasever, Ece Aksit, Senem Karabulut, Fatma Sen, Serkan Keskin, Leyla Kilic, İbrahim Yildiz, Hamza Ugur Bozbey, Derya Duranyildiz, Sezai Vatansever |
| Abstract |
The transforming growth factor beta 1 (TGFB1) is a regulatory cytokine with both tumor suppressor and tumor-promoting effects in breast cancer (BC) cell lines and tissue. Data about level of circulating TGFB1 and its prognostic significance in BC patients is conflicting. The objective of this study is to determine the clinical significance of the serum TGFB1 levels in BC patients. We enrolled 96 female patients with histopathologically diagnosed BC who did not receive chemotherapy (CT) or radiotherapy. Serum TGFB1 levels were measured by ELISA method and compared with 30 healthy controls. The mean serum TGFB1 level of BC patients was significantly higher than controls (0.08 vs. 0.04 ng/ml, p < 0.001). There was no significant difference according to known disease-related clinicopathological or laboratory parameters. Serum TGFB1 level had a significant impact on overall survival in both univariate (p = 0.01) and multivariate analysis (p = 0.013). Serum TGFB1 level is elevated in BC patients and has a favorable prognostic value. However, it has no predictive role on CT response. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 29% |
| Student > Ph. D. Student | 6 | 29% |
| Student > Bachelor | 3 | 14% |
| Researcher | 2 | 10% |
| Professor | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 2 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 29% |
| Biochemistry, Genetics and Molecular Biology | 5 | 24% |
| Immunology and Microbiology | 3 | 14% |
| Agricultural and Biological Sciences | 2 | 10% |
| Business, Management and Accounting | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 3 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2014.
All research outputs
#15,299,919
of 22,754,104 outputs
Outputs from Tumor Biology
#1,050
of 2,622 outputs
Outputs of similar age
#133,147
of 226,130 outputs
Outputs of similar age from Tumor Biology
#35
of 82 outputs
Altmetric has tracked 22,754,104 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,622 research outputs from this source. They receive a mean Attention Score of 2.2. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,130 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 82 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.